Bristol Myers Squibb (BMY) Equity Average (2009 - 2026)

Bristol Myers Squibb (BMY) has 17 years of Equity Average data on file, last reported at $19.3 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $19.3 billion, up 153.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 billion (up 153.49% YoY), and the FY2025 annual result was $16.7 billion, up 149.78% from the prior year.
• Equity Average grew to $19.3 billion in Q1 2026 per BMY's latest filing, from $18.5 billion in the prior quarter.
• Over five years, Equity Average peaked at $19.3 billion in Q1 2026 and troughed at -$22.6 billion in Q1 2024.
• A 5-year average of -$1.1 billion and a median of $173.0 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average slumped 4474.62% in 2024, then surged 3094.18% in 2025.
• A 5-year view of Equity Average shows it stood at -$1.1 billion in 2022, then surged by 1356.93% to $13.3 billion in 2023, then slumped by 43.0% to $7.6 billion in 2024, then soared by 143.84% to $18.5 billion in 2025, then advanced by 3.96% to $19.3 billion in 2026.
• Business Quant data shows BMY's Equity Average at $19.3 billion in Q1 2026, $18.5 billion in Q4 2025, and $9.3 billion in Q3 2025.